Animalcare Group (ANCR) CMD 2026 summary

Strategic Vision and Growth Ambitions

• Targeting GBP 150 million revenue by 2030, driven by organic growth, M&A, and innovation, with ambitions to expand further beyond 2030.

• Focused on strengthening core brands, expanding into new geographies, and leveraging a balanced, diversified growth plan across three strategic pillars.

• Strategic investments in sales force, commercial excellence, and dental channel expansion underpin near-term growth.

• Ongoing investment in R&D, aiming for 5% of revenues annually, with a robust pipeline including small molecules and VHH antibody technologies.

• M&A strategy prioritizes accretive, culture-aligned acquisitions, with GBP 25 million firepower and openness to equity raises for larger deals.

Operational and Financial Transformation

• Improved average margin from 50% in 2020 to 65% in top 10 products, with debt reduced from GBP 26 million to GBP 9 million and leverage below 1x.

• Top 10 product revenue grew 28%, with 95% now owned brands, enhancing control and sustainability.

• Manufacturing network consolidation underway, aiming to unlock EBITDA and revenue gains by reducing partners and improving supply chain reliability, with full completion targeted by 2029.

• Commercial excellence initiatives, including unified CRM and targeted onboarding, are forecast to deliver incremental EBITDA from 2027.

• EBITDA margin targeted at 25% by 2030, with cash conversion above 80% and margin targets of 60%-65%.

Innovation, Pipeline, and Market Expansion

• R&D pipeline expanded from one asset in 2020 to six, with two recent launches and a focus on pain, inflammation, and dermatology in companion animals and equine.

• Proprietary VHH antibody technology positioned as a differentiator, with plans for multi-species applications and global expansion, targeting the $2–3bn companion animal pain market by 2033.

• Randlab acquisition has strengthened equine market presence, now 24% of business, and serves as a blueprint for international growth.

• Dental franchise to expand into omni-channel and online retail, targeting 20% CAGR in OTC portfolio over five years, leveraging digital marketing and retail partnerships.

• Geographic expansion prioritized in France, Italy, Germany, Australia, New Zealand, and the U.S., with InVetro investment supporting growth in Australia and an option to increase stake in 2029.